Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Melbourne investor briefing presentation 29 July 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased provide the following presentation which will be used in the Company’s investor briefing being held in Melbourne on 29 July 2026. The presentation highlights the Company's recent clinical, operational and corporate achievements, including completion of enrolment in Regimen I of the HEALEY ALS Platform Trial, and the strategic importance of the Company's supply agreement with Elanco in supporting the long-term development pathway for NUZ-001. The presentation also provides an overview of upcoming clinical, regulatory and operational milestones expected to shape the Company's next phase of development. Event details Date Wednesday, 29 July, 2026 Time 5:00 – 7:00pm AEST Location Gilbert + Tobin meeting room Level 25/101 Collins Street, Melbourne RSVP irpr@irdepartment.com.au – please note in your email that you would like to attend the Neurizon Melbourne investor briefing event. A copy of the presentation follows this release. -ENDS- This announcement has been authorised for release by the Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited. For further information, please contact: Marketing & Corporate Affairs Lidija Damjanovic Neurizon Therapeutics Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Investor Relations Henry Jordan Six Degrees Investor Relations Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 Shaping the future of neurodegenerative diseases Neurizon Therapeutics Update - July 2026 Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. 2 Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. Investor Presentation - July 2026 To lead the development of neurodegenerative treatments towards a promising new horizon for patients. Our Vision 4 INVESTMENT HIGHLIGHTS Approaching a value-defining readout 01 Why ALS (Amyotrophic Lateral Sclerosis) – ALS is a rapidly progressive, uniformly fatal neurodegenerative disease that destroys motor neurons, with typical survival of 2-3 years from diagnosis – Two approved ALS therapies (2-6 months survival benefit)1 – ~35k US diagnosed2; ~55k target markets – US Total Addressable Market (TAM) of US$5B3 02 Why now – Enrolled in registrational Phase 2/3 HEALEY ALS Trial under Regimen I — 250 participants, 3:1 ratio – Recruitment completed ahead of schedule – Topline readout: late Q2 CY2027 03 Early clinical signals (Ph 1 and Open Label Extension) – Functional improvement: 31% slower functional, 43% slower respiratory decline (matched historical controls from the PRO-ACT Historical Database4) – Estimated life extension of ~16 months5 04 Why NUZ-001 – Differentiated, oral mechanism targeting 97% of ALS disease pathology – FDA & EMA orphan designations; patent runway to 2041 – Potential FDA accelerated-approval eligibility 1. Quigley, et al.. 2025. doi.org/10.1007/s40263-025-01217-0;.2. Center for Disease Control (CDC); 3Assuming WAC of US$150k/patient/year; 4. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834; 5. Neurizon Phase 1 and Open Label Extension Study data from February 2026 PROMISING EARLY SIGNALS 71% lower risk of death vs matched controls5 HR 0.29 · 95% CI 0.13–0.64 · p=0.002 · Phase 1 + OLE, n=12 Investor Presentation - July 2026 ALS: High Unmet Need with Significant Value Potential Investor Presentation - July 2026 5 Multiple large-value transactions and deals in recent years Key ALS Value Reference Point: Shionogi – RADICAVA US$2.5B Transaction (April 2026)1 Transaction: Shionogi acquired global rights to RADICAVA (IV edaravone) and RADICAVA ORS (oral edaravone) from Tanabe Pharma. Deal value: US$2.5 billion upfront (lump sum), with potential additional royalties on future sales (subject to conditions). Timing: Announced 22 December 2025 and completed in early April 2026 Asset profile: A commercial, revenue-generating ALS therapy franchise with both IV and oral formulations already in market. Strategic rationale: Strengthened Shionogi’s rare disease commercial platform (especially US), adding established programs/teams and readiness to launch additional rare disease treatments. Other Recent ALS Deals Eli Lilly entered neurodegenerative disease collaborations with Alchemab2 (2025; reported up to US$415M) and QurAlis3 (2024; US$45M upfront plus potential milestones). Eli Lilly and Verge Genomics4 entered an ALS discovery collaboration in 2021. Public reports described potential transaction economics of approximately US$694M. Ferrer: Prilenia and Ferrer announced a strategic collaboration and licensing agreement relating to pridopidine in 2025.5 1. Shionogi press release, 22 December 2025; transaction completion announced April 2026. 2. Alchemab Therapeutics press release, 6 May 2025 3. QurAlis press release, 3 June 2024 4. Fierce Biotech, 6 January 2021 5. Prilenia Therapeutics press release, 28 April 2025 6 Neurizon: From Scientific Origin to Clinical Execution A unique, advanced opportunity in neurodegenerative diseases Well characterised drug Disease-modifying potential Strong foundation Late-stage clinical execution 1 2 3 4 5 DISCOVERY & FOUNDATION CLINICAL VALIDATION & HEALEY SELECTION 2005 - 2013 TRANSLATION TO HUMAN DISEASE 2013 - 2021 NEURIZON FORMATION & STRATEGY 2022 - 2023 2024 - 2025 CLINICAL EXECUTION 2026 - 2027 Monepantel – a proven veterinary product with extensive safety and pharmacology data From veterinary use to potential in neurodegenerative diseases Building a focused clinical-stage company with the clear focus on neurodegenerative diseases NUZ-001 Phase 1 results show early signals of efficacy in a small study with people living with ALS/MND and drive inclusion into HEALEY trial Active execution of Registrational Phase 2/3 HEALEY ALS Platform Trial NUZ-001 is a well-characterised molecule, with novel neurodegenerative biology, and is now advancing through a registrational Phase 2/3 ALS clinical program Investor Presentation - July 2026 NUZ-001 is being evaluated inside the largest independently sponsored ALS trial platform in the world 7 NUZ-001 is independently adjudicated, randomised Ph2/3 asset with potential for accelerated approval Independent sponsorship and validation Access into the HEALEY program is competitive, selection of NUZ-001 is validating. The platform is sponsored by the Sean M. Healey & AMG Center for ALS at Mass General Brigham, which holds the IND. Protocol, randomisation, conduct and data management sit with HEALEY. Established site network Regimen I utilises a strong existing, independent clinical infrastructure. The purpose-built network of expert ALS centres across US operates under a single master protocol. Standardised conduct and oversight FDA-approved Master Protocol, central DSMB. Applied learnings from previous Regimens Demonstrated execution Enrolment completed in under five months from first participant dosing is the fastest enrolment of any regimen in the platform to date. This indicates investigator support and participant demand. WHAT HEALEY STUDY EVALUATES • Efficacy of NUZ-001 on function and survival • Extended safety profile • CSF exposure • TDP-43 / proteostasis mechanistic hypothesis through exploratory biomarkers • Suitability and utility of digital biomarkers for disease progression Subject to positive study results study enables potential registration pathway. Investor Presentation - July 2026 Participants living with ALS enrolled 250 Activated across the United States 78 SITES From first participant dosing to enrolment completion <5 MONTHS Regimen I is designed to provide clinical signal 8 REGIMEN I AT A GLANCE Design Double-blind, placebo-controlled adaptive Phase 2/3 under the HEALEY master protocol Participants 250 enrolled at close of recruitment (protocol expanded from 160 to 240 in May 2026) Randomisation 3:1 NUZ-001 to placebo — a fully concurrent, internally consistent placebo arm Dose and route 10 mg/kg once daily, oral — the dose carried forward from the Phase 1 MEND open-label extension Treatment period 36-week double-blind period, followed by a 36-week active treatment extension Primary endpoint Change in ALSFRS-R from baseline to Week 36 Key secondaries Slow vital capacity baseline to Week 36 Freedom from death or permanent assisted ventilation from baseline to Week 36 Eligibility Within 24 months of symptom onset; SVC & NfL threshold per master protocol; stable background riluzole / edaravone permitted 36-week blinded period Earlier HEALEY regimens read out at 24 weeks. A longer blinded window gives more time for functional curves to separate in a disease where treatment effects accumulate slowly and variably, and optimises the chance of showing a clinically meaningful treatment effect. Fully concurrent placebo arm Regimen I carries its own placebo group rather than borrowing shared platform controls, removing the temporal-drift and comparability associated with pooled placebos. Exploratory Endpoints WHY THESE DESIGN CHOICES MATTER Recruitment complete July CY2026 All participants enrolled and dosing commenced RCT Completion Early Q2 CY2027 36-week randomised period, then active extension Database lock Q2 CY2027 Data cleaning and validation Topline result Late Q2 CY2027 Primary efficacy and safety readout Biological validation of disease progression and mechanism of action through extensive exploratory biomarker panel (NfL, TDP-43, mtDNA, protein panel, speech) Investor Presentation - July 2026 9 FDA EMA PMDA Orphan Drug Designation Type C Meeting Q2 2024 Q3 2026 HEALEY Topline Results Late Q2 2027 Orphan Drug Designation Q4 2024 Scientific Protocol Advice Meeting Q3 2026 General Consultation Q2 2026 ODD Application H2 2027 JNDA Application H2 2028 MAA Submission H1 2028 NDA Submission H1 2028   IND Clearance Q3 2025  NUZ-001 Regulatory Strategy for ALS Market Access Progressing a considered regulatory strategy across key jurisdictions, with a primary focus on the US  Investor Presentation - July 2026 Phase 1 Open Label Extension Generated clinical signals and established long-term tolerability to warrant clinical advancement 10 Primary Outcome • Long-term treatment with NUZ-001 at the recommended Phase 2/3 dose was safe and well-tolerated Slowed Functional Decline Respiratory Stabilisation Survival* • Sustained slowing in disease progression by 31% compared to PRO-ACT matched controls* • No study discontinuations; • Several participants still accessing NUZ- 001 under the TGA’s Special Access Scheme Highlights (Based on a study population of n=12 patients) • Reduction in the risk of death by 71% compared to PRO-ACT matched controls • Estimated life extension of ~16 months • 43% reduction in VC PP compared to PRO-ACT matched controls* * Neurizon Phase 1 and Open Label Extension Study data from February 2026 Biomarker Trends • Stable plasma NfL and decreased (–17%) urinary p75ECD Patient Satisfaction Investor Presentation - July 2026 -2.93 -1.65 -5 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 PRO-ACT Matched Controls (n=420) NUZ-001 (n=12) -1.21 -0.83 -2 -1.8 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 PRO-ACT Matched Controls (n=360) NUZ-001 (n=12) ALSFRS-R Slope (points/month) Phase 1 Open Label Extension Preliminary Efficacy ALSFRS-R and SVC 11 Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent predicted (PP) when compared to matched controls from the PRO-ACT historical database1 1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834 2. Forced vital capacity (FVC) was used when SVC was not collected 3. Matched on time since onset, baseline ALSFRS-R, pre-baseline slope, and disease onset location Motor Function – ALSFRS-R Difference 0.37 points/month (p=0.145) Difference 1.27 points/month (p=0.078) 31% 43% Respiration – SVC PP2 3 3 VC PP Slope (points/month) Investor Presentation - July 2026 Phase 1 Open Label Extension NUZ-001 shows improved survival vs matched controls 12 NUZ-001 treatment resulted in statistically significantly longer survival of participants with ALS, (X2=11.35, p=0.00075), compared to matched controls1 from the PRO-ACT database2 1. Matched on time since onset, baseline ALSFRS-R, pre-baseline ALSFRS-R slope, and disease onset location 2. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834 Analysis suggests that treatment with NUZ-001 reduces the risk of death by 71%: Hazard ratio of 0.29 (95% CI: (0.131, 0.644), p = 0.0024) Investor Presentation - July 2026 Comparison of Approved ALS Treatments & NUZ-001 Riluzole1 (Rilutek®) Edaravone2 (Radicava®) Amx00353,4 (Relyvrio®) Tofersen6 (Qalsody®) ALSFRS-R (Improvement Compared to Placebo) Not evaluated Not evaluated FVC/SVC (Improvement Compared to Placebo) Survival (Improvement Compared to Placebo) NUZ-0017 ~3 months 33.20% (p=0.0013) 23.43% (FVC, p=0.0942) ~6 months 23.27% (p=0.030) 22.37% (SVC, p=0.080) ~6.5 months5 14.74% (p=0.970) 35.59% (SVC, p>0.05) Not evaluated 39% (p=0.080)10 48% (SVC, p=0.058)10 31% (p=0.145)10 41% (SVC, p=0.078)10 ~16 months10 24 weeks 24 weeks 28 weeks 116 weeks9 40 weeks8 1. N Engl J Med. 1994 Mar 3;330(9):585–9;2. Lancet Neurol 201716: 505-12; 3. N Engl J Med 2020; 383:919-30; 4. Voluntary removal from the market; 5. Muscle Nerve. 2021 Apr;63(4):31–39.6. Engl J Med 2022:387:1099-110; 7. Neurizon data on file; 8. Median treatment period in Phase 1 MEND Study; 9. Median treatment period for combined Phase 1 MEND Study and OLE Study; 10. Comparison to matched untreated controls in PRO-ACT Database; 11. Research Reports World 2024; 12. BioPharma Dive, ALS Drug Development, September 30, 2025; 13. Biogen 2025 Annual Report; Verified Market Report 2025; 02 (2017) 01 (1995) 03 (2022) 04 (2023) Phase 1 study supports potential for significantly improved outcomes compared to existing treatments 52 weeks n=77 n=69 n=89 n=72 n=12 n=250 in ongoing p2 Investigational 13 Annual Sales Generic, ~US$40 mil in sales11 ~US$1 bn in peak sales11 >US$400m sales12 ~US$86.9m sales13 Investor Presentation - July 2026 NUZ-001 demonstrates encouraging biomarker trajectory When compared with ALS natural history database 14 • NfL is a widely recognized, sensitive biomarker for ALS. The structural protein is released into the CSF (cerebrospinal fluid) or serum when nerves are damaged. It has been used as a surrogate endpoint for Accelerated Approvals for ALS therapeutic candidates. • Stable neurofilament (NfL) and p75 serum concentrations during NUZ-001 treatment suggest reduced disease pathology progression Benatar et al. (2024): serum NfL; Neurizon Phase 1: plasma NfL. Absolute values are not directly comparable due to matrix and assay differences. Data shown for contextual purposes only. Contrasting reference ALS data using standard of care (Benatar et al. 2024 “Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.” eBioMedicine 108: 105323. https://doi.org/10.1016/j.ebiom.2024.105323.) Investor Presentation - July 2026 TDP-43 aggregates 15 FUS = Fused in Sarcoma; SOD1 = Superoxide Dismustase 1; TDP-43 = Transactive response DNA-binding protein 43 ALS Patient Population1 Spinal Cord Clearance of misfolded proteins in healthy motor neuron <1% FUS Mutation ~2% SOD1 Mutation 97% TDP-43 Aggregation Protein aggregates are cleared by multiple pathways including autophagy-lysosomal and ubiquitin-proteasome systems. Together these systems help to maintain proteostasis. TDP-43 Aggregates are a Hallmark of ALS Pathology Investor Presentation - July 2026 1. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013 Aug 7;79(3):416-38. doi: 10.1016/j.neuron.2013.07.033. PMID: 23931993; PMCID: PMC4411085. NUZ-001 prevents TDP-43 aggregation and restores neuronal function in human iPSC models 16 STMN2/DAPI TDP43/DAPI STMN2 = Stathmin-2; TDP-43 = Transactive response DNA-binding protein 43 1. Klim, Joseph R., Luis A. Williams, Francesco Limone, et al. 2019. “ALS-Implicated Protein TDP-43 Sustains Levels of STMN2, a Mediator of Motor Neuron Growth and Repair.” Nature Neuroscience 22 (2): 167–79. https://doi.org/10.1038/s41593-018-0300-4.. Investor Presentation - July 2026 0 50 100 Control Stressor 0.31 μM 0.63 μM 1.25 μM 2.2 μM 4.4 μM TDP-43 aggregation (% Change to MG-132) 7 Day NUZ-001 vs MG132 treatment of TDP43 M337V motor neurons 0.00 0.02 0.04 0.06 Control Stressor 0.31 μM 0.63 μM 1.25 μM 2.5 μM 5 μM STMN2 spots per neurite surface area (µm²) 7 Day NUZ-001 vs MG132 treatment of TDP43 M337V motor neurons NUZ-001 prevents the formation of TDP-43 aggregates and loss of Stathmin-21 expression iPSC Motor Neurons Stressor Stressor NUZ-001: Platform Optionality for Proteinopathy-Driven Diseases 17 TDP-43 ALS/AD/PD/FTD/CTE Amyloid beta AD/PD Tau AD/PD/FTD/CTE/PSP alpha Synuclein AD/PD NUZ-001 is a mechanism-driven, disease-agnostic approach to treating neurodegeneration by rebalancing proteostasis and addressing core cellular dysfunction. AD = Alzheimer’s Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson’s Disease; PSP = Progressive Supranuclear Palsy Strong mechanistic rationale for potential efficacy across a wide array of neurodegenerative diseases. Impaired proteostasis contributes to the formation of intracellular inclusion bodies of misfolded proteins, a hallmark of neurodegenerative diseases. mHTT HD New preclinical data show NUZ-001 increases activity of multiple protein clearance pathways in neuronal models: autophagy and proteasomal systems. Investor Presentation - July 2026 Capital Management Update Disciplined execution — three-part funding strategy progressing in line with expectations 18 Capital Allocation Funding Strategy — Three-Part Framework ↓ Non-clinical spend reduced Pre-clinical, marketing, administrative and travel costs all decreased, reflecting the Company's commitment to limiting spend not directly focused on the HEALEY ALS Platform Trial. ↑ Clinical spend increased as planned Clinical expenditure increased consistent with the planned ramp-up in HEALEY ALS Platform Trial activity as participant enrolment progressed through the quarter. ✓ HEALEY expansion: no funding impact Expansion to 250 participants expected to have no impact on funding requirements through anticipated Q2 CY2027 topline results, supported by philanthropic funding and cost discipline. PLACEMENT COMPLETE Approximately A$2.7m raised through placement of the Entitlement Offer shortfall, further underpinning the Company's balance sheet Pro-rata non-renounceable Entitlement Offer completed in the prior period R&D TAX REBATE ONGOING Advance Overseas Finding (AOF) provides a cash rebate on qualifying HEALEY ALS Platform Trial expenditure Non-dilutive, binding on the Australian Tax Office and AusIndustry — a key complementary funding source that can be accelerated CONVERTIBLE NOTE FACILITY& ALTERANTIVE SOURCES OF FUNDING AVAILABLE Obsidian Global GP, LLC facility remains an available and flexible source of funding Company remains committed to evaluating all funding alternatives prior to further drawdown, with a view to protecting shareholder interests and minimising dilution 18 Investor Presentation - July 2026 Funding Strategy — Three-Part Framework Expanding Relationship with Elanco The License Agreement was a foundational step that formalized Neurizon's relationship with Elanco and which provides supports future regulatory approval and commercialisation. This agreement is an exclusive global licensing agreement that provides worldwide rights to utilise Elanco's intellectual property for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Elanco is now a top five shareholder in Neurizon and has appointed an experienced business development executive as a Board Observer. Through its participation in the December 2025 share placement, Elanco is a top five shareholder in Neurizon. It has also appointed Justine Conway (Global Head of Business Development) as a Board Observer. Supports Neurizon’s advanced clinical positioning and commercial readiness Neurizon has executed a long-term supply agreement with Elanco strengthening commercialisation readiness The agreement provides long-term access to human health GMP monepantel, the active pharmaceutical ingredient in Neurizon’s lead asset, NUZ-001. It is an important commercialisation milestone and materially strengthens Neurizon’s long-term manufacturing and supply certainty and commercialization readiness. License Agreement Strategic Investment Supply Agreement 19 Relationship with Elanco strengthens Neurizon’s position as a clinically advanced, commercially focused and capital efficient neurodegenerative disease company. Investor Presentation - July 2026 Key Progress and Upcoming Milestones 20 ONGOING EFFORTS  Additional work on validating mechanism of action and broader pipeline  Partnership expansion opportunities with patient associations  Targeted engagement with potential strategic partners • CEO Appointment • Preclinical updates • HEALEY tablet supply secured through completion • EMA Protocol Advice opinion • Ongoing partnering discussions • Participation at investment and scientific conferences Preclinical Updates Commercial Supply Agreement with Elanco HEALEY Regimen I Completed Enrolment Ethics Approval for Liquid Formulation PK Study EMA Scientific Advice preparation PMDA Regulatory Consultation Data Strengthening MOA Understanding Key Progress in Q2/Q3 Upcoming Milestones Q3/Q4 Investor Presentation - July 2026 HEALEY Regimen I update Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com Thank You